Metsera (NASDAQ:MTSR) Raised to Hold at Wall Street Zen

Key Points

• Metsera (NASDAQ:MTSR) has been upgraded from a "sell" rating to a "hold" rating by Wall Street Zen in a recent research note.
• Bank of America has increased its target price for Metsera from $45.00 to $50.00, while Leerink Partners set a target price of $77.00 with an "outperform" rating.
• Hedge funds have shown increased interest, with notable stake increases, including a 100% increase in position by BNP Paribas Financial Markets during the second quarter.

Metsera (NASDAQ:MTSR - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued to investors on Monday.

Several other analysts have also issued reports on MTSR. Bank of America boosted their target price on Metsera from $45.00 to $50.00 and gave the company a "buy" rating in a research note on Thursday, August 28th. Leerink Partners began coverage on Metsera in a research note on Tuesday, September 9th. They issued an "outperform" rating and a $77.00 target price on the stock. Leerink Partnrs upgraded Metsera to a "strong-buy" rating in a research note on Tuesday, September 9th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Metsera in a research report on Wednesday, September 3rd. Finally, Wells Fargo & Company started coverage on Metsera in a research report on Friday, June 20th. They issued an "overweight" rating and a $65.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $63.50.

Metsera Stock Performance

Shares of MTSR opened at $35.67 on Monday. The stock's fifty day moving average price is $35.49 and its two-hundred day moving average price is $28.91. Metsera has a 1 year low of $12.30 and a 1 year high of $47.40.

Metsera (NASDAQ:MTSR - Get Free Report) last issued its earnings results on Monday, July 28th. The company reported ($0.66) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Metsera

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Osaic Holdings Inc. grew its position in Metsera by 45.5% during the second quarter. Osaic Holdings Inc. now owns 946 shares of the company's stock worth $27,000 after buying an additional 296 shares in the last quarter. BNP Paribas Financial Markets grew its position in Metsera by 100.0% during the second quarter. BNP Paribas Financial Markets now owns 1,600 shares of the company's stock worth $46,000 after buying an additional 800 shares in the last quarter. Police & Firemen s Retirement System of New Jersey grew its position in Metsera by 32.6% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 4,293 shares of the company's stock worth $122,000 after buying an additional 1,056 shares in the last quarter. Prudential Financial Inc. grew its position in Metsera by 7.9% during the second quarter. Prudential Financial Inc. now owns 16,070 shares of the company's stock worth $457,000 after buying an additional 1,170 shares in the last quarter. Finally, New York State Common Retirement Fund grew its position in Metsera by 25.0% during the second quarter. New York State Common Retirement Fund now owns 6,000 shares of the company's stock worth $171,000 after buying an additional 1,200 shares in the last quarter.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.